By the University of Manchester’s estimates, $2.4 billion has been invested in graphene research. In 2014, Lux Research projected a 2025 global market of $349 million for the material; however, in 2013, sales of graphene totaled only $12 million. Manufacture of the material has accelerated, with total production capacity of graphene nanoplatelets in the Americas; […]
As the importance of the Chinese market has grown, so have foreign companies’ R&D efforts in the country. According to a survey of 477 US companies conducted by the American Chamber of Commerce in the People’s Republic of China (AmCham) and Bain & Company in February, 46% of the companies classified as R&D Intensive Industries […]
Productivity growth for instrument and laboratory product companies decelerated in fiscal year 2014 (FY14) due to the negative currency impact on revenue growth for most US companies, varied market demand and increased investments in personnel. With half of the companies recording productivity gains, the average sales-per-employee ratio for the 20 companies in the table on […]
A recent survey of 40 senior executives in China, across the aerospace and defense, automotive, consumer products, engineering and industrial products, and metal industries, and conglomerates, found that most plan to increase R&D spending. While only 65% of the companies spent 4% or more of revenues on R&D in the past two years, 93% plan […]
By 2025, according to Citigroup estimates, the South Korean market for biosimilars will reach $18 billion, with companies investing $110 billion in their development. South Korea aims to build this market to order to elevate its status as a global pharmaceutical supplier, increase its pharmaceutical exports to $20.5 billion and have 3 of the top […]
This month, China’s State Council revealed “Made in China 2025,” a plan to elevate China’s global position in manufacturing. The plan is the first in a series of three, which by 2049 are meant to establish the country as “a leading manufacturing power.” China’s premier, Li Keqiang, said at the annual session of the National […]
Expectations for industry growth showed little change compared to last fall (see IBO 10/15/14), according to IBO’s biannual Business Climate Survey. However, compared to a year ago, sentiments were more restrained. This spring, 57% of survey participants expect instrument and laboratory product–industry sales to increase moderately. Forty-three percent expect them to stay the same. However, […]
IBO has moved up its quarterly financial review of major publicly held instrument and lab product businesses to the mid-month issues in order to provide more time-sensitive reporting. In addition, IBO has reorganized its Sales Indexes to one primary Laboratory Instruments and Products Sale Index, which will be presented in the May 31 issue. These […]
The Korea National Food Cluster, or Foodopolis, will be built in Iksan, South Korea, and open by June 2016. It will be the site of R&D for about 150 food companies. The center is expected to create 22,000 jobs and generate $14 billion in processed and value-added products each year. Three R&D facilities are planned: […]
“The Nature Index 2015” for the Asia-Pacific region was released in March. The Index tracks articles published in selected science journals chosen by a group of independent researchers, and is used to assess the impact and productivity of countries. A country’s weighted fractional count (WFC) is a measure of articles with authors from a country, […]
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
